The Case for GNMT as a Biomarker and a Therapeutic Target in Pancreatic Cancer
| Autor: | Zachary Heinzman, Connor Schmidt, Marek K. Sliwinski, Nalin C. W. Goonesekere |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Pharmaceuticals, Vol 14, Iss 3, p 209 (2021) |
| Druh dokumentu: | article |
| ISSN: | 14030209 1424-8247 |
| DOI: | 10.3390/ph14030209 |
| Popis: | The high mortality rate for pancreatic cancer (PC) is due to the lack of specific symptoms at early tumor stages and a high biological aggressiveness. Reliable biomarkers and new therapeutic targets would help to improve outlook in PC. In this study, we analyzed the expression of GNMT in a panel of pancreatic cancer cell lines and in early-stage paired patient tissue samples (normal and diseased) by quantitative reverse transcription-PCR (qRT-PCR). We also investigated the effect of 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranoside (PGG) as a therapeutic agent for PC. We find that GNMT is markedly downregulated (p < 0.05), in a majority of PC cell lines. Similar results are observed in early-stage patient tissue samples, where GNMT expression can be reduced by a 100-fold or more. We also show that PGG is a strong inhibitor of PC cell proliferation, with an IC50 value of 12 ng/mL, and PGG upregulates GNMT expression in a dose-dependent manner. In conclusion, our data show that GNMT has promise as a biomarker and as a therapeutic target for PC. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|